ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy?

ImageneBio, Inc. (NASDAQ:IMA) rose 2.4% on Thursday . The stock traded as high as $7.09 and last traded at $6.70. Approximately 88,116 shares changed hands during mid-day trading, an increase of 111% from the average daily volume of 41,829 shares. The stock had previously closed at $6.54.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on IMA shares. Wall Street Zen lowered shares of ImageneBio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Wedbush lowered shares of ImageneBio from a “neutral” rating to an “underperform” rating in a report on Tuesday, November 25th. Finally, Leerink Partners assumed coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $26.50.

ImageneBio Price Performance

The stock has a market cap of $74.91 million, a price-to-earnings ratio of -0.83 and a beta of 0.43. The business’s 50 day moving average is $6.73 and its 200 day moving average is $8.52.

Insiders Place Their Bets

In other news, Director Joseph P. Slattery bought 16,000 shares of the business’s stock in a transaction dated Wednesday, December 24th. The shares were acquired at an average price of $5.99 per share, for a total transaction of $95,840.00. Following the completion of the transaction, the director owned 16,000 shares of the company’s stock, valued at approximately $95,840. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of ImageneBio by 170.8% in the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after acquiring an additional 6,810 shares during the period. Goldman Sachs Group Inc. purchased a new stake in ImageneBio in the 4th quarter valued at $76,000. Millennium Management LLC acquired a new stake in ImageneBio during the 4th quarter worth $79,000. Bridgeway Capital Management LLC acquired a new stake in ImageneBio during the 3rd quarter worth $104,000. Finally, NewEdge Advisors LLC purchased a new position in ImageneBio during the 3rd quarter worth $106,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.